Inflammatory Liver Disease

Liver disease develops as a consequence of uncontrolled inflammation and fibrosis resulting in global mortality of over 2 million deaths per year. Within our diverse Birmingham region, the high prevalence of obesity (30%), rising alcohol-use disorders, and social inequities, contribute to sustained pressures on liver services. All liver diseases are driven by immune dysregulation and persistent hepatic inflammation, resulting in cirrhosis, liver failure and hepatocellular carcinoma (HCC). Thus, new therapies targeting inflammation have the potential to prevent or reverse progression to end-stage liver disease.

Liver with inflammatory liver disease

Theme Leads

Phil Newsome
Professor Phil Newsome

Professor Phil Newsome

Shishir Shetty

Professor Shish Shetty

Related news

New research into autoimmune liver condition suggests unique cell movements may be driving disease

A study from our NIHR Birmingham Biomedical Research Centre's Inflammatory liver disease theme has revealed that

A milestone achievement: 3,000 patients have joined the NAFLD BioResource

In a bid to unravel the complexities of Non-Alcoholic Fatty Liver Disease (NAFLD), the NIHR NAFLD

Promising target for liver disease treatments identified

An international clinical trial involving Birmingham Professor Phil Newsome identified a promising target for patients with